Saxagliptin mitigates doxorubicin-induced cardiotoxicity by modulating NLRP3/caspase-1/IL-1β and TLR-4/NF-κB pathways
Toxicology and Applied Pharmacology · 2026
DOI: 10.1016/j.taap.2025.117697 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicology and Applied Pharmacology, 2026. Verfasst von Maha M Abdel-Fattah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology and Toxicology Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt. Electronic address: mahamohammed@pharm.bsu…. Hauptthemen laut MEDLINE: Dipeptides, NLR Family, Pyrin Domain-Containing 3 Protein, NF-kappa B, Doxorubicin. Die Arbeit nennt 52 Literaturangaben.
Abstract (Originalsprache)
Doxorubicin (DOX) is a powerful anthracycline utilized in the management of several malignant disorders, involving both solid and hematological tumors. Despite its effectiveness as cytotoxic agent, its therapeutic use is restricted as cardiac toxicity proportional to the drug dosage. Saxagliptin (SAXA) is a selective and potent member of the dipeptidyl peptidase (DPP)-IV inhibitor family utilized in the management of type two diabetes. It also possesses several biological actions, involving anti-inflammatory and antioxidant properties. This work sought to ascertain the underlying molecular mechanisms and determine the shielding role of SAXA against DOX-induced cardiotoxicity. Thirty-two rats were randomly assigned to four experimental groups, including a normal control group administered the vehicle only, a SAXA group receiving SAXA alone (10 mg/kg), a DOX control group receiving DOX (20 mg/kg) as a single dose, and a SAXA treatment group receiving SAXA plus DOX. Compared to DOX control group, pretreatment with SAXA (10 mg/kg) significantly reduced serum concentrations of CK-MB and CTnI by 37.11 % and 46.32 %, respectively, in addition to a marked improvement in the histopathological features of heart tissues. Moreover, SAXA significantly decreased MDA by 56.05 % and increased GSH and SOD in DOX-intoxicated rats by 493.28 % and 458.32 %, respectively. Additionally, western blot analysis revealed that SAXA pretreatment significantly down-regulated TLR-4 and NLRP3 by 34.9 % and 33.99 %, respectively. Furthermore, ELISA analysis showed that SAXA pretreatment significantly down-regulated NF-κB, caspase-1, and IL-1β by 44.04 %, 78.7 %, and 57.7 %, respectively. The findings of this study suggest that SAXA may exert a cardioprotective effect against DOX-induced toxicity, likely through its antioxidant and anti-inflammatory properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt. Electronic address: mahamohammed@pharm.bsu.edu.eg.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt.
Zitieren
APA
Abdel-Fattah, M. M., Abozaid, Y. M., Messiha, B. A. S., & Khalaf, M. M. (2026). Saxagliptin mitigates doxorubicin-induced cardiotoxicity by modulating NLRP3/caspase-1/IL-1β and TLR-4/NF-κB pathways. Toxicology and Applied Pharmacology. https://doi.org/10.1016/j.taap.2025.117697
Vancouver
Abdel-Fattah MM, Abozaid YM, Messiha BAS, Khalaf MM. Saxagliptin mitigates doxorubicin-induced cardiotoxicity by modulating NLRP3/caspase-1/IL-1β and TLR-4/NF-κB pathways. Toxicology and Applied Pharmacology. 2026. doi:10.1016/j.taap.2025.117697
BibTeX
@article{AbdelFattah2026,
author = {Abdel-Fattah, Maha M and Abozaid, Yasmeen M and Messiha, Basim Anwar Shehata and Khalaf, Marwa M},
title = {Saxagliptin mitigates doxorubicin-induced cardiotoxicity by modulating NLRP3/caspase-1/IL-1β and TLR-4/NF-κB pathways},
journal = {Toxicology and Applied Pharmacology},
year = {2026},
doi = {10.1016/j.taap.2025.117697}
}
EUVIMED